A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects With Moderate-to-severe Atopic Dermatitis
Latest Information Update: 03 Oct 2023
Price :
$35 *
At a glance
- Drugs Tozorakimab (Primary)
- Indications Atopic dermatitis; Eczema
- Focus Therapeutic Use
- Acronyms FRONTIER-AD
- Sponsors AstraZeneca; AstraZeneca AB
- 11 Oct 2022 Status changed from active, no longer recruiting to completed.
- 06 Oct 2022 This trial has been completed in Germany (End Date: 11 Aug 2022) according to European Clinical Trials Database record.
- 22 Apr 2022 Planned End Date changed from 13 Oct 2022 to 20 Sep 2022.